Omega Stock Performance

OMGA
 Stock
  

USD 5.58  0.21  3.91%   

On a scale of 0 to 100, Omega Therapeutics holds a performance score of 5. The company holds a Beta of 0.214, which implies not very significant fluctuations relative to the market. Let's try to break down what Omega's beta means in this case. As returns on the market increase, Omega Therapeutics returns are expected to increase less than the market. However, during the bear market, the loss on holding Omega Therapeutics will be expected to be smaller as well. Although it is vital to follow Omega Therapeutics current trending patterns, it is good to be conservative about what you can do with the information regarding equity existing price patterns. The philosophy towards forecasting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Omega Therapeutics technical indicators, you can presently evaluate if the expected return of 0.48% will be sustainable into the future. Please employ Omega Therapeutics information ratio, value at risk, kurtosis, as well as the relationship between the sortino ratio and semi variance to make a quick decision on whether Omega Therapeutics historical price patterns will revert.
  
Omega Performance
5 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Omega Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak technical and fundamental indicators, Omega Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

Omega Price Channel

Quick Ratio14.93
Fifty Two Week Low1.98
Target High Price30.00
Fifty Two Week High31.41
Target Low Price4.00

Omega Therapeutics Relative Risk vs. Return Landscape

If you would invest  462.00  in Omega Therapeutics on July 7, 2022 and sell it today you would earn a total of  96.00  from holding Omega Therapeutics or generate 20.78% return on investment over 90 days. Omega Therapeutics is currently generating 0.4802% in daily expected returns and assumes 6.1276% risk (volatility on return distribution) over the 90 days horizon. In different words, 53% of stocks are less volatile than Omega, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Omega Therapeutics is expected to generate 4.94 times more return on investment than the market. However, the company is 4.94 times more volatile than its market benchmark. It trades about 0.08 of its potential returns per unit of risk. The DOW is currently generating roughly -0.04 per unit of risk.

Omega Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Omega Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Omega Therapeutics, and traders can use it to determine the average amount a Omega Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0784

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsOMGA
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns
Estimated Market Risk
 6.13
  actual daily
 
 53 %
of total potential
 
5353
Expected Return
 0.48
  actual daily
 
 9 %
of total potential
 
99
Risk-Adjusted Return
 0.08
  actual daily
 
 5 %
of total potential
 
55
Based on monthly moving average Omega Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Omega Therapeutics by adding it to a well-diversified portfolio.

About Omega Therapeutics Performance

To evaluate Omega Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Omega Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Omega Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Omega Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Omega's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt natures operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes to down-regulate the expression of SFRP1, a protein that inhibits hair growth and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Things to note about Omega Therapeutics

Checking the ongoing alerts about Omega Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Omega Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Omega Therapeutics Alerts

Equity Alerts and Improvement Suggestions

Omega Therapeutics has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 412 K. Net Loss for the year was (74.96 M) with loss before overhead, payroll, taxes, and interest of (47.72 M).
Omega Therapeutics currently holds about 200.8 M in cash with (70.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.2.
Over 91.0% of the company shares are owned by institutional investors
Latest headline from www.benzinga.com: Omega Therapeutics to Participate in Two Upcoming Investor Conferences - Omega Therapeutics - Benzinga
Please check Your Equity Center. Note that the Omega Therapeutics information on this page should be used as a complementary analysis to other Omega Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Omega Stock analysis

When running Omega Therapeutics price analysis, check to measure Omega Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omega Therapeutics is operating at the current time. Most of Omega Therapeutics' value examination focuses on studying past and present price action to predict the probability of Omega Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Omega Therapeutics' price. Additionally, you may evaluate how the addition of Omega Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Is Omega Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Omega Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.